SILO.US Silo Pharma Inc

Healthcare Biotechnology USA Stocks
1.71 USD
Close of Nov 18, 2026
1.10 10.43
Market cap
USD 3.69M
P/E
-
P/B
0.74x
ROE
-44.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SILO.US undervalued?

Graham number

The Graham number of Silo Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Silo Pharma Inc fundamental analysis

No fundamental analysis for Silo Pharma Inc yet.

Silo Pharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Silo Pharma Inc

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-indu…

Full company profile